细胞治疗诱导肝移植免疫耐受临床研究进展

Clinical research progress on cell therapy induced immune tolerance in liver transplantation

  • 摘要: 肝移植是终末期肝病的首选治疗方法,但受者需长期进行免疫抑制治疗以控制排斥反应,这可能导致并发症,从而影响受者的长期生存。免疫耐受是指器官移植受者在不依赖长期免疫抑制药的情况下,免疫系统仍能维持对移植物的耐受状态。免疫耐受状态是器官移植领域追求的“理想目标”,可减少药物不良反应并提高长期生存率。细胞治疗在诱导肝移植术后免疫耐受展现出良好的前景。因此,本文就调节性T细胞、调节性树突状细胞、间充质干细胞、造血干细胞等细胞治疗在肝移植免疫耐受诱导中的应用进展综述,以期为肝移植术后免疫耐受诱导的临床应用提供参考。

     

    Abstract: Liver transplantation is the preferred treatment for end-stage liver disease, but recipients require long-term immunosuppressive therapy to control rejection, which may lead to complications and affect their long-term survival. Immune tolerance refers to the ability of organ transplant recipients to maintain their immune system's tolerance to the graft without relying on long-term immunosuppressants. Immune tolerance is an ideal goal pursued in the field of organ transplantation, which can reduce adverse drug reactions and improve long-term survival rates. Cell therapy has emerged as a promising strategy to induce such tolerance after liver transplantation. Therefore, this article reviews the application progress of cell therapies such as regulatory T cells, regulatory dendritic cells, mesenchymal stem cells, hematopoietic stem cells, etc. in inducing immune tolerance after liver transplantation, in order to provide reference for the clinical application of immune tolerance induction after liver transplantation.

     

/

返回文章
返回